Maxim Group Has Lowered Expectations for scPharmaceuticals (NASDAQ:SCPH) Stock Price

scPharmaceuticals (NASDAQ:SCPH - Get Free Report) had its price target cut by investment analysts at Maxim Group from $20.00 to $12.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. Maxim Group's target price would suggest a potential upside of 283.39% from the company's previous close.

Separately, HC Wainwright reaffirmed a "buy" rating and set a $18.00 target price on shares of scPharmaceuticals in a research report on Thursday.

scPharmaceuticals Trading Up 4.3 %

Shares of NASDAQ:SCPH traded up $0.13 during midday trading on Thursday, reaching $3.13. The company had a trading volume of 485,705 shares, compared to its average volume of 325,961. The company has a fifty day simple moving average of $3.27 and a two-hundred day simple moving average of $3.75. The firm has a market cap of $157.39 million, a price-to-earnings ratio of -1.65 and a beta of 0.40. The company has a debt-to-equity ratio of 1.66, a quick ratio of 6.89 and a current ratio of 8.08. scPharmaceuticals has a 1-year low of $2.75 and a 1-year high of $5.65.

scPharmaceuticals (NASDAQ:SCPH - Get Free Report) last issued its earnings results on Wednesday, March 19th. The company reported ($0.35) earnings per share for the quarter, beating analysts' consensus estimates of ($0.40) by $0.05. The company had revenue of $12.15 million for the quarter, compared to the consensus estimate of $12.08 million. scPharmaceuticals had a negative return on equity of 244.93% and a negative net margin of 264.60%. Research analysts predict that scPharmaceuticals will post -1.53 earnings per share for the current year.

Remove Ads

Institutional Investors Weigh In On scPharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the stock. Wealthedge Investment Advisors LLC bought a new position in scPharmaceuticals during the fourth quarter worth $69,000. ProShare Advisors LLC acquired a new position in shares of scPharmaceuticals during the fourth quarter worth $48,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of scPharmaceuticals by 36.1% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,973 shares of the company's stock valued at $78,000 after acquiring an additional 5,827 shares during the last quarter. Deutsche Bank AG lifted its holdings in scPharmaceuticals by 514.5% during the 4th quarter. Deutsche Bank AG now owns 82,488 shares of the company's stock worth $292,000 after buying an additional 69,064 shares during the period. Finally, Captrust Financial Advisors lifted its stake in shares of scPharmaceuticals by 116.1% in the fourth quarter. Captrust Financial Advisors now owns 40,062 shares of the company's stock worth $142,000 after acquiring an additional 21,523 shares during the period. 89.52% of the stock is owned by institutional investors.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.